This company has been acquired
GreenLight Biosciences Holdings Management
Management criteria checks 3/4
GreenLight Biosciences Holdings' CEO is Andrey Zarur, appointed in Aug 2008, they has a tenure of 14.92 years. Their total yearly compensation is $576.56K , comprised of 99.7% salary and 0.3% bonuses, including company stock and options. They directly owns 0.59% of the company’s shares, worth $268.37K. The average tenure of the management team and the board of directors is 1.3 years and 4.4 years respectively.
Key information
Andrey Zarur
Chief executive officer
US$576.6k
Total compensation
| CEO salary percentage | 99.7% |
| CEO tenure | 14.9yrs |
| CEO ownership | 0.6% |
| Management average tenure | 1.3yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$577k | US$575k | -US$167m |
| Sep 30 2022 | n/a | n/a | -US$163m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$129m |
| Dec 31 2021 | US$728k | US$500k | -US$112m |
| Sep 30 2021 | n/a | n/a | -US$86m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$450k | -US$53m |
Compensation vs Market: Andrey's total compensation ($USD576.56K) is about average for companies of similar size in the US market ($USD749.31K).
Compensation vs Earnings: Andrey's compensation has been consistent with company performance over the past year.
CEO
Andrey Zarur (52 yo)
14.9yrs
Tenure
US$576,561
Compensation
Dr. Andrey Juan Zarur, Ph.D. Co-founded GreenLight Biosciences Holdings (aka GreenLight Biosciences, Inc) in 2008 and serves as its President and Chief Executive Officer since August 2008. Dr. Zarur serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.9yrs | US$576.56k | 0.59% $ 268.4k | |
| CFO & Interim Chief Accounting Officer | 4.2yrs | US$1.28m | 0% $ 0 | |
| Chief Operating Officer | 7.5yrs | US$1.30m | 0% $ 0 | |
| Co-founder and Chief Sustainability & Strategy Officer | less than a year | no data | 0.020% $ 8.9k | |
| Chief Technology Officer | 1.3yrs | no data | no data | |
| General Counsel | less than a year | no data | no data | |
| Senior VP & Head of Corporate Affairs | 2.5yrs | no data | no data | |
| Advisor | no data | no data | 0% $ 0 | |
| Chief Commercial Officer & General Manager of Plant Health | 2.4yrs | no data | 0% $ 0 | |
| Chief Medical Officer | less than a year | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Rollover Investor | less than a year | no data | 0.018% $ 8.1k |
1.3yrs
Average Tenure
52yo
Average Age
Experienced Management: GRNA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.9yrs | US$576.56k | 0.59% $ 268.4k | |
| Independent Director | 4.1yrs | US$293.23k | 0% $ 0 | |
| Independent Chairman of the Board | 12.6yrs | US$429.53k | 0.20% $ 91.5k | |
| Independent Director | 8.5yrs | US$293.23k | 0% $ 0 | |
| Advisor | no data | no data | no data | |
| Board Observer | 4.2yrs | no data | no data | |
| Independent Director | 5.4yrs | US$293.23k | 0% $ 0 | |
| Board Observer | 4.2yrs | no data | no data | |
| Board Observer | 4.2yrs | no data | no data | |
| Advisor | no data | no data | no data | |
| Independent Director | 4.6yrs | US$293.23k | 0.042% $ 19.1k | |
| Board Observer | 4.2yrs | no data | no data |
4.4yrs
Average Tenure
57.5yo
Average Age
Experienced Board: GRNA's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/25 10:39 |
| End of Day Share Price | 2023/07/21 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GreenLight Biosciences Holdings is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Burleson | Canaccord Genuity |
| John Ezekiel Roberts | Credit Suisse |